SmartTRAK analyzes how COVID-19 and vaccinations will impact the US Advanced Wound Care Market in 2021.

The impact of COVID-19 on life in the US and its onslaught into the US health care system began in mid-March. CMS and the American College of Surgeons recommended that hospitals, physicians and clinics halt all non-essential medical and surgical procedures, including the treatment of many types of wounds. However, the continual care of a chronic wound is essential for patients to ensure it is on the correct trajectory to heal. Typically, clinicians treat chronic wounds at least once a week to assess the progress of the wound, provide debridement and/or apply CTPs (skin substitutes). The hospital outpatient department (HOPD) wound clinics have been the primary site-of-care to treat these wounds but with the closing of several of these facilities during the initial COVID surge, many patients with chronic wounds were not seen, delayed treatment or began the transfer to the physician office for treatment. In fact, there is some evidence that wounds increased in severity since the start of the pandemic resulting in greater use of higher technology products and unfortunately, an increase in amputations.

The most significant impact on the market occurred in April/May 2020 when several states went into lock down and most, if not all, elective procedures were cancelled. SmartTRAK analyzed the Advanced Wound Care market back in April with the assumption that the peak of COVID-19 would occur during April/May and would slowly return to normal in a v-shaped or hockey-stick shaped recovery. However, data show COVID-19 did not peak solely in the April/May time frame ...

SmartTRAK reviews the impact and underlying reasons behind the high turnover rate among CEOs in the wound care market.

At the end of November 2020, Zlatko Rihter assumed his role as the new CEO for Mölnlycke*, which means that all top four Advanced Wound Care players now have CEOs with less than three years in office. As a matter of fact, seven or eight of the top 10 players have appointed new CEOs in the last three years, depending on how you count Acelity being acquired by 3M.

The average time in office for a CEO among the 2,500 largest public companies is around seven years. Most of the transitions are planned (70%), some are forced out (15%), and some are consequences of mergers (15%). In US hospitals, the turnover rate among CEOs is close to six years.

While the reason for replacing the CEO is sometimes not clear, in most cases it is. SmartTRAK reviews what is behind the transition in CEOs at the top wound care companies and what it means for the Advanced Wound Care market, which is estimated to be have generated $7.4B in the last 12 months according to SmartTRAK forecasts.

SmartTRAK reviews the 2020 Virtual EWMA meeting covering the impact of COVID-19, the growing use of digital tools and emerging technologies 

For the first time, the European Wound Management Association (EWMA) annual meeting, held November 18 – 19^th 2020, was an all-virtual event. As the premier wound care conference in Europe, EWMA 2020 showcased the latest news and trends in the market for European Advanced Wound Dressings, which is projected to reach $1.8B in 2020 according to SmartTRAK estimates. It turned into a truly global event thanks to the format that welcomed 9,758 registered participants from 113 countries from all over the world.

SmartTRAK examines the Top 5 countries in Europe during the time of COVID-19 and estimates how the Advanced Wound Dressing Market will be impacted in 2020 and 2021.

Using an elbow bump instead of a handshake or hug is not the only new routine people have learned during the pandemic. As winter arrives with an expected surge in COVID-19, healthcare systems and services in Europe are building on lessons learned from the spring outbreak to help shape the way health services will be delivered in the coming months.

Amid this pandemic, several factors are affecting growth in the European Advanced Dressings Market, which is projected to reach ~$2.07B (€1.85B) by 2024 according to SmartTRAK estimates. In this article, SmartTRAK reviews how the COVID-19 pandemic has evolved in Europe and how it is impacting the market for Advanced Dressings in France, Germany, the UK, Spain and Italy.

Q3 makes a recovery from Q220 losses but gains remain below pre-COVID levels

For Q320, according to BioMedGPS’ SmartTRAK Financial Dashboard, the US Infection Prevention-Vascular Access Adjunct Products market was down -1.8% YoY. Leading manufacturers in this segment hit hard in Q220 by COVID-19 restrictions and elective procedure cancellations reported positive growth over Q2, but are still not at pre-COVID-19 levels.

Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 Infection Prevention: US Vascular Access Adjunct Market Recap* are:

In Q320, Advanced Wound Care bounced back to almost normal levels amidst the COVID-19 pandemic with patients returning for chronic wound treatment.

For Q320, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenues for Advanced Dressings, External Devices and Biologics increased slightly YoY.

3M* remained the WW market leader, up +1.5% YoY, driven by tentative signs of improvement in elective procedures. WW Advanced Dressings returned to positive growth, with mixed performance among leading players. US Skin/Dermal Substitute (CTP) revenue rebounded over Q319, driven by a whopping performance by Organogenesis, while WW NPWT was down slightly YoY, with single-use down and traditional devices flat.

Among the many topics covered in the comprehensive Q320 Advanced Wound Market Recap* are:

The US market for Hemostats and Sealants began the journey back to normalcy, slipping -0.2% YoY in Q320, as elective surgeries began to be performed again. Hemostats led the charge with Sealants not far behind.

As the US healthcare system begins to manage COVID-19 and elective procedures return toward pre-COVID-19 levels, the US Hemostats and Sealants market rebounded with a drop of only -0.2% YoY in Q320 according to SmartTRAK Financial Dashboard. Most manufacturers still experienced declines in Q320, but far narrower than the losses of Q220. Ethicon* managed a +4.5% gain in Q320 while the other manufacturers essentially treaded water with respect to Q319.

Among the many topics covered in the comprehensive Q320 US Hemostats and Sealants Market Recap* are:

The US Surgical Matrices Market rebounded toward pre-COVID-19 levels in Q320 as the numbers of hernia and breast surgeries came closer to normal levels. The recovery was somewhat uneven, with Breast Matrices still off -8.6% YoY, while Hernia Matrices were closer to pre-COVID-19 levels, off -2.5% YoY.

As hospitals began to establish a new normal in the time of COVID-19, the US Surgical Matrices Market rebounded to lose only -4.6% YoY according to BioMedGPS’ SmartTRAK Financial Dashboard. AbbVie* (formerly Allergan) held on to its lead despite the effects of the pandemic, as its breast-heavy portfolio showed a slower return to normal. Becton Dickinson* (BD) lost less than AbbVie/Allergan, declining –3.5% YoY, as hernia procedures bounced back to normal levels a little faster.

Among the many topics covered in the comprehensive Q320 US Surgical Matrices Market Recap* are:

In recent years, leading manufacturers of static compression devices have expanded their product portfolios by investing in adjustable compression wraps (ACWs). A quick search in SmartTRAK shows that in 2014, Lohmann & Rauscher* acquired Solaris and added ReadyWrap*and TributeWrap brands to its portfolio. In 2016, Sigvaris* acquired Biacare, a US-based company with a strong reputation as a leader in the design and production of medical short-stretch wraps. Sigvaris now promotes and offers a range of compression wraps, including CompreFlex*and CoolFlex*. In 2019, medi* USA announced the launch of its new ready-to-wear circaid juxtalite hd inelastic compression wrap, and in 2020 Juzo*added a new compression wrap that has a slip-on feature and a new patent-pending inner connector.

Given the attention and investment dollars allocated to ACWs in recent years, this article explores the ACW market to provide greater visibility into key market dynamics, underlying value drivers and the outlook for future growth.

It is estimated that over 200 million people worldwide (WW) have venous and/or lymphatic conditions that are treatable with compression therapy. Some of the more common conditions include chronic edema, varicose veins, venous leg ulcers (VLUs), lymphedema and deep vein thrombosis. SmartTRAK estimates that ...

To download and read the complete Adjustable Compression Wraps Market Outlook article, please click the button below.

Despite the uncertainty of COVID-19, Skin Substitutes (CTPs) continue to push the boundaries in Advanced Wound Care with impressive clinical studies, new products and technologies, and changing market dynamics.

Despite the unpredictability of COVID-19, skin substitutes (CTPs – cellular and/or tissue-based products) continue to be a hot area of research, innovation and investment in the market for Advanced Wound Care (AWC). This segment is comprised of an assortment of products, including human dermal allografts, amniotic tissue allografts, xenografts, cell-based bioengineered and most recently synthetic type products. Wounds most often treated with these products include diabetic foot ulcers, venous leg ulcers, pressure ulcers, challenging surgical wounds, trauma wounds and burns. In addition, these wounds are treated in a variety of settings that include the hospital outpatient department (HOPD) wound clinic, physician office, surgical suite and burn center. In the following article, SmartTRAK reviews the latest news on skin substitutes (CTPs) from SAWC Spring 2020 and provides an update on investment activities as well as reimbursement and market trends amid COVID-19.